Physician profile
Thomas S Atkinson
NPI 1760758221
$650.09
in general payments reported to CMS, 2019-2025
15 companies · $198 in 2025
The $198 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $139 · 2021: $16.67 · 2022: $18.39 · 2023: $113 · 2024: $165 · 2025: $198.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $412 · Education: $64.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $411.89 |
| Education | $64.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $114.27 | 2019-2025 | |
| Pfizer INC. | $113.01 | 2021-2025 | |
| Daiichi Sankyo INC. | $84.01 | 2024 | Enhertu |
| Astrazeneca Pharmaceuticals LP | $61.49 | 2023-2025 | Enhertu |
| Mirati Therapeutics, INC. | $40.18 | 2023 | Krazati |
| Lilly USA, LLC | $37.43 | 2019-2024 | Retevmo, Jaypirca, Verzenio |
| Glaxosmithkline, LLC. | $30.65 | 2025 | Ojjaara, Blenrep |
| Takeda Pharmaceuticals U.S.A., INC. | $29.68 | 2019 | |
| Exelixis INC. | $27.74 | 2023 | Cabometyx |
| Merck Sharp & Dohme LLC | $27.11 | 2023 | Keytruda |
| Abbvie INC. | $19.77 | 2025 | |
| Genentech USA, INC. | $19.23 | 2024 | Venclexta |
| E.R. Squibb & Sons, L.L.C. | $17.18 | 2024 | |
| Lexicon Pharmaceuticals, INC. | $14.44 | 2019 | |
| Astellas Pharma US INC | $13.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Atkinson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.